Molecular Therapy: Oncology
Publisher: Elsevier · ISSN 2950-3299 · 73 articles
- Interleukin-21 expressing oncolytic vaccinia virus elicits systemic anti-tumor immune response and synergizes with immunotherapies
- CD4+ T cells are required for tumor antigen-expressing oHSV glioma therapeutic effect and antigen-specific antibody production
- PD-L1 transmembrane domain substitution overcomes CAR-T exhaustion driven by tonic signaling
- MRPL47 as a mitochondrial biomarker for early detection and therapeutic response in ovarian cancer
- ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models
- Therapeutic potential of oncolytic Zika virus in NF1-associated tumors
- PM54 induces transcriptional collapse across cell-derived and patient-derived cancer models
- An asymmetric split-costimulatory MSLN.BBz/NKG2D.28 dual CAR-T design enhances activity against antigenically heterogeneous pancreatic cancer
- Continuous in situ production of CAR T cells from in vivo-transduced HSCs is safe and delays growth of mouse HER2high tumors
- CARM1-expressing ovarian cancers are selectively sensitive to HSP70 inhibition
- The RNA-binding protein RPS3 accelerates cell cycling via the Wnt/β-catenin signaling pathway in pancreatic cancer
- CD26 cytoplasmic tail serves as a potential costimulatory domain in CAR-T cells
- First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report